CLOV trades 16.8% below Wall Street's consensus target of $5.63.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CLOV achieves its forward estimates and maintains a stable P/E multiple of 88.0x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 7, 2026, Clover Health Investments, Corp. (CLOV) has a Wall Street consensus price target of $5.63, based on estimates from 9 covering analysts. With the stock currently trading at $4.82, this represents a potential upside of +16.8%. The company has a market capitalization of $2.50B.
Analyst price targets range from a low of $5.00 to a high of $6.00, representing a 18% spread in expectations. The median target of $5.75 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 1 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 3 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, CLOV trades at a trailing P/E of 216.1x and forward P/E of 88.0x. Analysts expect EPS to grow +262.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HUMHumana Inc. | $52.1B | $433.74 | $470.42 | +8.5% | Hold | 47.4x | 44 |
 CVSCVS Health Corp. | $107.0B | $83.85 | $109.89 | +31.1% | Buy | 10.4x | 41 |
 ELVElevance Health Inc. | $92.3B | $425.62 | $466.69 | +9.6% | Buy | 14.7x | 38 |
 CNCCentene Corp. | $34.5B | $69.74 | $75.43 | +8.2% | Buy | 13.2x | 44 |
 MOHMolina Healthcare, Inc. | $10.9B | $208.99 | $216.73 | +3.7% | Buy | 39.7x | 39 |
 ALHCAlignment Healthcare, Inc. | $1.5B | $7.34 | $12.29 | +67.4% | Buy | — | 16 |
 OSCROscar Health, Inc. | $7.9B | $30.65 | $37.43 | +22.1% | Hold | 15.9x | 13 |
 BHVNBiohaven Ltd. | $2.2B | $14.48 | $24.67 | +70.4% | Buy | — | 25 |
 UNHUnitedHealth Group Incorporated | $357.9B | $394.15 | $478.68 | +21.4% | Buy | 19.1x | 52 |
 TDOCTeladoc Health, Inc. | $1.6B | $8.77 | $9.30 | +6.0% | Hold | — | 42 |
Quick answers to the most common questions about buying CLOV stock.
Clover Health Investments, Corp. (CLOV) has a consensus 12-month price target of $5.63, implying 16.8% upside from $4.82. The 9 analysts covering CLOV see moderate appreciation potential.
CLOV has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is leaning bearish, with 3 Sell/Strong Sell ratings. The consensus 12-month price target of $5.63 implies 16.8% upside from current levels.
At a forward P/E of 87.9562x, CLOV trades at a premium valuation. The consensus price target of $5.63 (16.8% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $6 for CLOV, while the most conservative target is $5. The consensus of $5.63 represents the median expectation. These targets typically reflect 12-month expectations.
CLOV is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 5 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CLOV stock forecast based on 9 Wall Street analysts shows a consensus price target of $5.63, with estimates ranging from $5 (bear case) to $6 (bull case). The median consensus rating is "Hold".
CLOV trades at a forward P/E ratio of 88.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 216.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on CLOV, with a "Hold" consensus rating and $5.63 price target (16.8% upside). 1 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CLOV analyst price targets range from $5 to $6, a 18% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5.63 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.